{"version":"1.0","type":"link","title":"Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.","author_name":"Tedeschi A 외","author_url":"https://prs-insight.online/author/Tedeschi%20A","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/163913","thumbnail_width":1200,"thumbnail_height":630}